A clinical and radiographic study to evaluate and compare the effectiveness of Nanocrystalline hydroxyapatite with Advanced Platelet Rich Fibrin and Hydroxyapatite reinforced Beta tri-calcium phosphate with A-PRF in the treatment of human infrabony defects A cross sectional study

Background: Combination of Nanocrystalline hydroxyapatite with Advanced Platelet Rich Fibrin and Hydroxyapatite reinforced Beta tri-calcium phosphate  with A-PRF for the treatment of infrabony defect will be effective in reduction of probing pocket depth, gain in clinical attachment level and defect fill Aim- To evaluate and compare the effectiveness of Nanocrystalline hydroxyapatite with Advanced platelet rich fibrinand Hydroxyapatite reinforced Beta tri-calcium phosphate  with A-PRF in the treatment of human infrabony defects clinically and radiographically using Cone beam computed tomography(CBCT). Materials and Methods: 28 defects will be randomly divided into test and control group consisting of 14 defects in each. Test group will be treated by Nanocrystalline hydroxyapatite particles with A-PRF and control will be treated by Hydroxyapatite reinforced Beta tri-calcuim phosphate with A-PRF .Primary outcomes will be radiographic bone fill and Secondary outcomes will be CAL gain and PPD reduction. The Clinical parameters will be recorded at baseline and 6 month postoperatively. Results:The Standard Deviation and Mean  values will be calculated for PI and papillary bleeding index and also for all clinical parameters including RGML, RAL, PPD, WKG and GR. To co-relate the data from base line to six months of each group students paired t-test will be used. To compare two groups at the day of surgery and six months student’s unpaired t-test will be used. Nanocrystalline hydroxyapatite particles with A-PRF will result in significantly greater CAL gain, PPD reduction and radiographic bone fill at 6 months when compared to Hydroxyapatite reinforced Beta tri-calcuim phosphate with A-PRF Conclusion: Combination of Nanocrystalline hydroxyapatite particles with A-PRF will be effective in the treatment of infrabony defects. Nanocrystalline hydroxyapatite particles with A-PRF will have significantly greater outcome as compared to Hydroxyapatite reinforced Beta tri-calcium phosphate with A-PRF.